Nvidia options pricing on Wednesday afternoon suggested traders expect shares to move roughly $10, or about 8%, in either direction around Wednesday’s earnings, which would be the stock's biggest post-earnings move since May.
Shares of medical tech company Masimo (NASDAQ:MASI) jumped 11.6% in the afternoon session after the company reported impressive fourth-quarter 2024 results, which beat analysts' revenue and EPS expectations. Sales grew 9% year on year, fueled by broad based demand. In addition, its full-year EPS guidance outperformed Wall Street's estimates by a wide margin. Zooming out, we think this was a solid quarter.
Shares of financial and compliance reporting software company Workiva (NYSE:WK) jumped 7.9% in the afternoon session after the company reported impressive fourth-quarter 2024 results, as revenue grew 20% year on year and slightly beat expectations, driven by strong demand for its subscription and support services. Billings also outperformed Wall Street's estimates, and the full-year 2025 sales outlook beat consensus expectations. On the other hand, its full-year EPS guidance missed significant
Shares of luxury electric car manufacturer Lucid (NASDAQ:LCID) fell 13.8% in the afternoon session after Bank of America downgraded the stock's rating from Neutral to Sell and lowered the price target from $3 to $1 following its mixed Q4 2024 earnings.
Shares of AppLovin tumbled as much as 22% on Wednesday after a pair of short seller firms published reports on the tech company, alleging a variety of fraudulent and deceptive practices.
Elon Musk's Department of Government Efficiency has so far had little to no impact on the government's $2 trillion annual deficits despite its ability to sow daily chaos around Washington, D.C.
Now on demand on WHAT THE TRUCK?!? Dooner is joined by Sean Dehan; David Bell; Steve Gold The post 3PL Summit: Truckstop’s state of the spot market | WHAT THE TRUCK?!? appeared first on FreightWaves.
Shares of speciality material and gas containment company Luxfer (NYSE:LXFR) fell 8.4% in the morning session after the company reported an underwhelming Q4 2024 result, as its full-year revenue and EBITDA guidance fell short of expectations. However, quarterly results were strong, with revenue, EPS, and EBITDA significantly surpassing analysts' estimates. Zooming out, we think this was a mixed quarter.
Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts' expectations, and sales were underwhelming, coming in line with expectations. We struggled to find many positives in these results, especially because EPS missed. Overall, this quarter could have been better.
Shares of advertising and marketing company Zeta Global (NYSE:ZETA) fell 13.8% in the pre-market session after the company reported weak fourth quarter 2024 results as its revenue guidance for next year suggests a significant slowdown in demand, and its revenue guidance for next quarter fell slightly short of Wall Street's estimates. On the other hand, Zeta reported optimistic EBITDA guidance for the next quarter, which blew past analysts' expectations, and its full-year EBITDA guidance trumped